Duphaston-Primed VS. GnRH Antagonist Ovarian Stimulation in PCOS: A Retrospective Review of Outcomes

Abstract

Introduction: To judge outcomes of fixed gonadotropin-releasing hormone antagonist (FGnRHan) protocol of OS versus fixed Duphaston-primed ovarian stimulation (D-POS) protocol regrades OS Response (OSR) in addition to pregnancy results in women diagnosed with PCOS who had submitted to ICSI&FET.Patients and Methods: A retrograde evaluation of PCOS females who underwent ICSI&FET cycles between February 2018 and February 2024 at Al Yasmine IVF center-Benha-Kalubia government and Hospital of Benha University (HBU). The outcomes included the frequency of pregnancy-related items, such as live birth rates, clinical pregnancy rates, and ongoing pregnancy rates as well as the incidence of OSR items such as fertilization rates, premature LH surge, and other OSR results.Results: The study encompassed 810 women, 390 undergoing D-POS, and 420 subjected to a GnRHan protocol. Baseline parameters exhibited similarity across both groups. Mature and fertilized oocytes demonstrated no significant disparity across both parties (P > 0.5). Instances of premature luteinization were infrequent in both parties, with no important statistical discrepancy (P > 0.5). Furthermore, there is no significant discrepancy (between the FD-POS and FGnRHan parties (48% [595/1240] vs.49% [564/1150], MD=1% [3% to 5%], P=0.62) regarding the clinical pregnancy average per frozen embryo transfer cycle (FTC). Parties' implantation and continuing pregnancy rates also remained statistically similar (P > 0.05). While the cost difference was considerably lower in D-POS than GnRHan group (5.5±2.3(4-8k) vs.8.1±3.3(6-11k), p =0.0001, k=1000LE)Conclusion:FD-POS protocol emerges as a potent, convenient, easy to use, cost-effective, with similar clinical outcomes alternative to the GnRHan protocol in PCOS patients who underwent ICSI&FET.